Decoy Therapeutics is trading at $5.24 (-6.60%) as the stock extends its pullback following a late-June rally tied to a $21 million private placement financing.
- The recent downward move appears to be driven by profit-taking and post-financing volatility rather than a fresh company announcement.
- No new company-specific catalysts were identified for July 20, 2026, suggesting the selling is primarily stock-specific and momentum-driven as the broader market remains mixed.